FDA Posts Untitled Letters Against Global API and Finished-Dose Manufacturers Across Four Countries

Enforcement pressure on foreign and domestic drug manufacturers is visible in the latest batch of compliance records posted to FDA's CDER FOIA Electronic Reading Room, with untitled letters spanning facilities in India, China, Italy, Germany, and the United States. For QA directors and regulatory affairs leads managing supplier qualification programs, the geographic spread reinforces that no single sourcing region carries a lower inspection risk profile.

The most recent actions, both dated 6/2/2026, target two U.S.-based firms: Formulated Solutions, LLC (FEI 3005779557) and Port Jervis Laboratories, Inc (FEI 1317131), with letters posted on 6/9/2026. Earlier records include a 5/16/2024 untitled letter to Laurus Synthesis Pvt. Ltd. in India (FEI 3011524794), posted 5/22/2024, and a 10/17/2024 letter to Shandong Boyuan Pharmaceutical Co. Ltd. in China (FEI 3008915591), posted 11/4/2024. Nectar Lifesciences Ltd., also India-based, received a letter dated 9/18/2023. The Italian firm Industria Farmaceutica Nova Argentina drew an untitled letter dated 9/9/2024.

Untitled letters sit below warning letters in 21 CFR Part 211 enforcement hierarchy but signal documented observations that have not been resolved to the agency's satisfaction. For supplier qualification teams, receipt of an untitled letter by an API or finished-dose contract manufacturer is a material event requiring reassessment under ICH Q10 quality management system principles, including documented CAPA review and, where applicable, alternate sourcing contingency planning.

The table also includes an Other Correspondence record for Aptar Radolfzell GmbH in Germany (dated 11/14/2024) and a 2021 untitled letter to Amazon.com, Inc., both of which reflect the breadth of FDA's compliance oversight beyond traditional dosage-form manufacturers. A 12/5/2022 letter to Valisure, LLC rounds out the posted records. Form FDA 483s and establishment inspection reports for these and other firms remain accessible through the Office of Inspections and Investigations (OII) FOIA Electronic Reading Room and the FDA Inspections Dashboard.

Plant heads and QA leads conducting annual product reviews or preparing for regulatory agency inspections should cross-reference their active supplier lists against the current CDER FOIA reading room, as posting dates lag record dates by days to weeks and new entries appear on a rolling basis.

Source: FDA CDER FOIA Electronic Reading Room via FDA.gov RSS Feed, 9 June 2026.